Bison Wealth LLC Sells 817 Shares of GSK plc (NYSE:GSK)

Bison Wealth LLC cut its holdings in shares of GSK plc (NYSE:GSK) by 6.8% in the 4th quarter, HoldingsChannel reports. The fund owned 11,244 shares of the pharmaceutical company’s stock after selling 817 shares during the period. Bison Wealth LLC’s holdings in GSK were worth $417,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Versant Capital Management Inc grew its position in GSK by 2,816.7% in the 4th quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company’s stock worth $26,000 after purchasing an additional 676 shares in the last quarter. Fairfield Bush & CO. bought a new stake in GSK in the 2nd quarter worth about $28,000. Larson Financial Group LLC grew its position in GSK by 271.8% in the 3rd quarter. Larson Financial Group LLC now owns 885 shares of the pharmaceutical company’s stock worth $32,000 after purchasing an additional 647 shares in the last quarter. BKM Wealth Management LLC bought a new stake in GSK in the 4th quarter worth about $32,000. Finally, SRS Capital Advisors Inc. grew its position in GSK by 52.9% in the 1st quarter. SRS Capital Advisors Inc. now owns 1,090 shares of the pharmaceutical company’s stock worth $39,000 after purchasing an additional 377 shares in the last quarter. 15.74% of the stock is owned by institutional investors.

GSK Stock Performance

Shares of GSK stock opened at $39.95 on Wednesday. The stock has a market capitalization of $82.78 billion, a P/E ratio of 13.27, a PEG ratio of 1.85 and a beta of 0.64. The company has a current ratio of 0.88, a quick ratio of 0.62 and a debt-to-equity ratio of 1.19. The firm’s 50 day moving average is $42.04 and its 200 day moving average is $38.76. GSK plc has a 12 month low of $33.33 and a 12 month high of $43.84.

GSK (NYSE:GSK) last announced its quarterly earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.72 EPS for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.04). The business had revenue of $10 billion for the quarter, compared to analysts’ expectations of $9.79 billion. GSK had a net margin of 16.24% and a return on equity of 51.45%. On average, sell-side analysts anticipate that GSK plc will post 4.03 earnings per share for the current year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, April 11th. Investors of record on Friday, February 23rd were paid a dividend of $0.3564 per share. This is a boost from GSK’s previous quarterly dividend of $0.34. This represents a $1.43 dividend on an annualized basis and a dividend yield of 3.57%. The ex-dividend date was Thursday, February 22nd. GSK’s dividend payout ratio is presently 52.82%.

Analyst Ratings Changes

A number of research firms have weighed in on GSK. Morgan Stanley began coverage on shares of GSK in a research note on Tuesday, January 23rd. They issued an “equal weight” rating on the stock. Jefferies Financial Group upgraded shares of GSK from a “hold” rating to a “buy” rating in a research note on Wednesday, January 3rd. Guggenheim upgraded shares of GSK from a “neutral” rating to a “buy” rating in a research note on Monday, March 4th. Finally, Citigroup upgraded shares of GSK from a “neutral” rating to a “buy” rating in a research note on Tuesday, February 13th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy”.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.